Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

Lignende værker

• Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
  af: Phillips, D C, et al.
  Udgivet: (2015)
• Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
  af: Bodo, Juraj, et al.
  Udgivet: (2016)
• ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
  af: Cang, Shundong, et al.
  Udgivet: (2015)
• Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
  af: Ackler, Scott, et al.
  Udgivet: (2015)
• The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
  af: Sandra Weller, et al.
  Udgivet: (2022-04-01)